Kim Chin K, Schmalfuss Carsten M, Schofield Richard S, Sheps David S
Cardiology Section, Department of Veterans Affairs, Medical Service, Malcom Randall VA Medical Center, Gainesville, Florida, USA.
Drugs. 2003;63(7):637-47. doi: 10.2165/00003495-200363070-00002.
Atherosclerosis is a disease process that affects the coronary, cerebral and peripheral arterial circulation. While great emphasis has been placed on the aggressive pharmacological management of coronary artery disease, less attention has been paid to the pharmacological management of peripheral vascular disease, despite its significant morbidity and mortality. The purpose of medical management in peripheral arterial disease is to relieve symptoms of claudication and to prevent thrombotic vascular events. These goals are best achieved through aggressive risk factor modification and pharmacotherapy. Risk factor modification includes smoking cessation, adequate control of blood pressure and cholesterol, as well as aggressive glycaemic control in patients with diabetes mellitus. Antiplatelet therapy and relief of claudication is also achieved through pharmacotherapy. With aggressive risk factor modification and adequate pharmacotherapy, patients with peripheral arterial disease can have an improved quality of life as well as prolonged survival.
动脉粥样硬化是一种影响冠状动脉、脑动脉和外周动脉循环的疾病过程。尽管人们高度重视冠状动脉疾病的积极药物治疗,但外周血管疾病的药物治疗却较少受到关注,尽管其具有显著的发病率和死亡率。外周动脉疾病的药物治疗目的是缓解间歇性跛行症状并预防血栓性血管事件。通过积极的危险因素修正和药物治疗能够最好地实现这些目标。危险因素修正包括戒烟、充分控制血压和胆固醇,以及对糖尿病患者进行积极的血糖控制。抗血小板治疗和间歇性跛行的缓解也可通过药物治疗实现。通过积极的危险因素修正和充分的药物治疗,外周动脉疾病患者的生活质量可以得到改善,生存期也可以延长。